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infarctionAbstract Objectives: This study assessed the cardio- and renoprotective effect of remote ischemic
Preconditioning (PreC) in patients undergoing percutaneous coronary intervention (PCI).
Background: Myocyte necrosis and contrast induced nephropathy (CIN) occur frequently in PCI
and are associated with subsequent cardiovascular events. Methods: Two hundred consecutive
patients undergoing elective PCI with normal baseline troponin-I (cTnI) values were recruited.
Subjects were systematically allocated into 2 groups: 100 patients received PreC (created by three
5 min inflations of a blood pressure cuff to 200 mmHg around the upper arm, separated by
5 min intervals of reperfusion) <2 h before the PCI procedure, and control group (n= 100).
Results: The incidence of PCI-related myocardial infarction (MI 4a) at 24 h after PCI was lower in
the PreC group compared with control group (41% vs 64%, P= 0.02). Subjects who received PreC
had significant trend toward lower incidence of CIN at 72 h after contrast exposure (4 vs. 11,
P= 0.05) and less chest pain during stent implantation compared to control group. At 3 months,
the major adverse event rate was lower in the PreC group (6 vs. 14 events; P= 0.04).
Conclusions: The use of PreC < 2 h before PCI, reduces the incidence of PCI-related MI 4a, tends
to decrease the incidence of CIN and improves ischemic symptoms in patients undergoing elective
PCI. The observed cardio- and renoprotection appears to confer sustained benefit on reduced major438055;
316 A.K.M. Hassan et al.adverse events at 3 month follow-up beyond what is seen with judicious pre- and post-hydration
(ClinicalTrials.gov identifier: NCT02313441).
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The first serendipitous description of ischemic Preconditioning
in 1986 found that intermittent and short-lived non-lethal
organ ischemia prior to significant ischemia–reperfusion
(I–R) induced a potent form of endogenous protection in the
recipient organ.1 Remote ischemic ‘pre-conditioning’ and
‘post-conditioning’ are now well-established mechanisms of
cytoprotection against ischemia–reperfusion injury, triggered
by intermittent Preceding ischemia prior to [remote Precondi-
tioning, PreC2,3] or after [remote post-conditioning, PostC4,5]
the index injury. This has been reflected in preliminary clinical
trials that demonstrate significant cardio- and renoprotection
in various settings.6–10
The implementation of PreC in clinical practice has been
difficult as it requires an intervention which must be imple-
mented before the onset of ischemia. Organ ischemia might
be predicted in medical interventions, such as percutaneous
coronary intervention (PCI) or cardiac surgery. PreC applies
brief controlled episodes of intermittent ischemia in peripheral
musculature of the arms or legs to evoke the signal of remote
conditioning using a simple and ubiquitous blood pressure
cuff, providing a means of safely applying this protection in
these patients without perceived side effects.11
Elective PCI is frequently associated with elevation of car-
diac troponin I (cTnI) and contrast induced nephropathy
(CIN).12–14 Type 4a myocardial infarction (MI) related to
PCI is defined as cTnI elevation 5 times > 99th centile of the
upper reference limit.15 PCI-related troponin elevation of this
magnitude and CIN correlates with a significant increase in
major adverse events (MAE).15 Micro-embolization of plaque
debris and side branch occlusion during PCI procedure16 and
cardiac reperfusion injury,17 have been proposed as the most
likely causes of PCI-related MI, with prognostic relevance.12
This single-center prospective non-randomized controlled
trial aimed to assess the cardio- and renoprotective effect of
remote PreC after elective PCI.2. Methods
2.1. Identification and recruitment of patients
We performed a prospective non-randomized parallel group
comparison at the catheterization laboratory of Assiut Univer-
sity Hospitals (AUH).
Patients between 18 and 80 years of age, scheduled to
undergo an elective PCI and able to give an informed consent
were eligible for enrollment in the study (Fig. 1, Table 1).
Elective PCI was defined as any coronary revascularization in
a low-risk, hemodynamically stable patient who presents to
the facility for a planned PCI or for a coronary angiogram fol-
lowed by ad hoc PCI. Exclusion criteria were as follows: (1)
emergency PCI; (2) baseline troponin value P0.04 ng/mL; (3)nicorandil or glibenclamide use; (4) those who could not give
informed consent; and (5) patients with severe renal impairment
or on regular dialysis as described in detail previously.18
2.2. Study groups and protocol
Consecutive patients undergoing elective PCI between Septem-
ber 2013 and May 2014, were invited to participate in the study
during their attendance at a routine preadmission clinic. Eligi-
ble patients, after obtaining informed consent, were systemat-
ically allocated to the PreC treatment group or the control
group according to our daily based allocation technique
(Fig. 1). 259 patients were screened for eligibility. Of the 259
patients screened, 18 were on nicorandil, 20 were on gliben-
clamide, and 11 had incomplete data. These 49 were excluded
from this analysis, leaving 210 participants for systematic allo-
cation, 10 of whom were dropped out of the study (Fig. 1).
PreC was successfully provided to 100 participants without
complication. Demographic and clinical details showed no dif-
ference between control and PreC groups (Table 1).
2.3. Pre- and post-procedural hydration protocols
Patients were hydrated with intravenous saline infusion as
prophylaxis against contrast induced nephropathy (CIN)
[3–4 mL/kg/h 4 h before and after intervention and encour-
aged to drink lots of water after PCI (except those with left
ventricular dysfunction or sever kidney disease, who under-
went hydration with 1 mL/kg/h for 12 h before and after
PCI)] as described in detail previously.19,20
2.4. Assignment method
Participants were allocated to the treatment group by a day-
dependent method of allocation. The analysis was blinded as
all outcome measures were recorded by an independent
researcher without prior knowledge of the study allocation
of the participants. The study protocol was approved by the
ethical committee of Assiut faculty of medicine (IRB no:
IRB00008718 at 23 June 2013). A written informed consent
was obtained from all participants. The consent form was
designed with an explanation on the purpose and conduction
of this research project. The study identification number at
ClinicalTrials.gov.is NCT02313441.
2.5. Sample size power calculation
The sample size was determined on the basis of the primary
outcome, post-PCI cTnI at 24 h. PreC was estimated to reduce
the prevalence of PCI-induced cTnI release by 15% as
described in detail previously.18 A power calculation
(a= 0.05; b= 0.2; statistical power = 80%) estimated a sam-
ple size of 100 patients per group would be needed. Hence 200
Figure 1 Flow of patients through the study. * = dropout. RIPC = remote ischemic pre-conditioning; PCI = percutaneous coronary
intervention; Pt. = patients.
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such a reduction to be detected.
2.6. Study intervention
2.6.1. PreC and control intervention
Patients in the remote PreC had a blood pressure cuff placed
on their upper arm <2 h before the PCI procedure. The blood
pressure cuff was inflated to a pressure of 200 mmHg for
5 min, followed by 5 min of deflation to allow reperfusion.
This procedure was repeated 3 times followed by deflation
and progress to PCI as described in detail previously.18 Con-
trol participants did not experience transient upper-limb
ischemia.2.6.2. PCI procedure
PCI was performed using femoral approach in all our patients
using 6 French guiding catheters. Ultravist (iopromide; Bayer
Schering Pharmaceuticals, Berlin, Germany) was used as intra-
coronary contrast. Participants were pre-treated with aspirin
150 mg and clopidogrel 600 mg orally before the procedure,
and intraprocedural intravenous heparin bolus 10,000 IU.
Glycoprotein IIb/IIIa inhibitors, stent implantation and all
other medication were given at the discretion of the primary
operator, adhering to best conventional clinical practice.
2.6.3. Post-procedure care
Participants were managed conventionally following PCI, as
described in detail previously, including a period of in-patient
Table 1 Demographic and clinical data of participants used remote ischemic preconditioning and control groups before percutaneous
coronary intervention.
Variable Control
(N= 100)
PreC
(N= 100)
P
Age (years) 56 ± 10 57 ± 9 NS
Male Gender, n (%) 76(76%) 80 (80%) NS
Risk factors
Smoking, n (%) 45 (45%) 47 (47%) NS
Hypertension, n (%) 42 (42%) 46 (46%) NS
Dyslipidemia, n (%) 28 (28%) 31 (31%) NS
Diabetes Mellitus, n (%) 35 (35%) 32 (32%) NS
BMI, median (IR) 27.5 (25.4–30.2) 27.3 (25.5–30.1) NS
History of CKD, n (%) 18 (18) 20 (20) NS
Clinical details
LVEF (%) 59 ± 9 60 ± 10 NS
Previous PCI, n (%) 8 (8%) 7 (7%) NS
Previous CABG, n (%) 5 (5%) 6 (6%) NS
Time since the latest angina before PCI < 24 h, n (%) 22 (22%) 21 (21%) NS
Angina CCS grade III/IV, n (%) 23 (23%) 24 (24%) NS
Hemoglobin (mg/dl) 12 ± 2 12 ± 3 NS
Baseline SCr, (mg/dl) 0.95 ± 0.31 0.98 ± 0.39 NS
Baseline eGFR (mL/min/1.73 m2) 85 (64–91) 71 (64–88) NS
Medications, n (%)
Chronic aspirin therapy 94 (94%) 100 (100%) NS
Chronic clopidogrel therapy 44 (44%) 56 (56%) NS
ACEI or ARB 70 (70%) 68 (68%) NS
Statins 94 (94%) 95 (95%) NS
Beta-blockers 80 (80%) 79 (79%) NS
Data are presented as mean ± standard deviation, number (%) of patients or median (interquartile range). ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CCS, Canadian Cardiology Society; CKD, chronic kidney
disease; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; PreC, remote
ischemic preconditioning; NS, not significant; PCI, percutaneous coronary intervention; SCr, serum creatinine.
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clopidogrel for 1 month in case of a bare-metal stent and for
1 year in case of a drug eluting stent as described in detail
previously.21
2.7. Data collection
2.7.1. Biochemical assays
Blood samples were taken on the morning of admission to the
hospital, when patients had been fasting for more than 10 h
(baseline), and again 24 h after PCI for serum cTnI and serum
creatinine. Another venous blood sample was taken on day 3
after PCI for assessment of serum creatinine level and esti-
mated glomerular filtration rate (eGFR).
cTnI was analyzed with an automated immunoassay (Bayer
ADVIA IMS Troponin-I Ultra method, Bayer, Berlin,
Germany). The 99th percentile of the cTnI level in a reference
population (upper reference limit) of healthy volunteers was
below the lower limit of detection of 0.04 ng/mL. The variation
coefficient, a measure of precision within the analytical
range, is <10%, complying with the European Society of
Cardiology/American College of Cardiology consensus
requirements.22 The analytical range was 0.01–50 ng/mL, with
an assay sensitivity of 0.006 ng/mL. The European Society of
Cardiology/American College of Cardiology/American Heart
Association/World Health Federation definition of a PCI-
related MI (MI 4a) was defined as >0.20 ng/mL (5 times the
upper reference limit).15 Serum creatinine was analyzed usingthe Dimension Xpand Plus assay (Siemens Diagnostics; upper
limit of normal (ULN) = 115 lmol/L). The eGFR was calcu-
lated according to the Modification of Diet in Renal Disease
(MDRD) formula.23 CIN was defined as an increase in the
serum creatinine level of more than 0.5 mg/dl or more than
25% from baseline within 3 days after procedure without
any other identifiable cause of acute kidney injury.24
All biochemical measurements were made at the end of the
study by two independent researchers (M.H.M.A. & H.A.A.)
without knowledge of the study allocation of the participants.
2.7.2. Peri-procedural parameters
Arterial blood pressure was measured by monitoring intra-
aortic pressure through guiding catheter without guide wire.
Heart rate was measured by real-time electrocardiographic
monitoring at the moment of balloon inflation. Occurrences
of angina (chest pain, tightness, and similar symptoms of
myocardial ischemia) during PCI were assessed. Chest pain
severity during PCI was graded on a scale of 0 for no pain
to 10 for the most severe discomfort ever experienced. Angio-
graphic success was defined as a residual stenosis of <15% by
visual angiographic assessment and the absence of thrombosis
or dissection. Procedural factors, including length and type of
implanted stent, duration and pressure of coronary balloon
inflations, and other variables, were recorded by an indepen-
dent researcher without prior knowledge of the study alloca-
tion of the participants. Peri-procedural parameters were
described and used in detail previously.18,20
Table 2 Angiographic and periprocedural data of participants systematically allocated to remote ischemic
preconditioning and control groups.
Parameter Control (N= 100) PreC (N= 100) P
Angiographic parameters
Target vessel, n (%)
LM 3 (3%) 4 (4%) NS
LAD 45 (45%) 40 (40%) NS
LCx 17 (17%) 20 (20%) NS
RCA 23 (23%) 22 (22%) NS
Combined 15 (15%) 18 (18%) NS
Side branch > 2 mm, n (%) 34 (34%) 30 (30%) NS
CTO, n (%) 9 (9%) 10 (10%) NS
Subtotal occlusion, n (%) 14 (14%) 19 (19%) NS
Lesion type (AHA/ACC), n (%) NS
A 34 (34%) 28 (28%)
B 37 (37%) 33 (33%)
C 29 (29%) 37 (37%)
PCI-related parameters
Predilation 39 (39%) 40 (40%) NS
Postdilation 22 (22%) 24 (24%) NS
Number of DES 22 (22%) 24 (24%) NS
Mean number of stents per case 1.6 ± 0.5 1.6 ± 0.7 NS
Mean stent diameter per case, mm 2.9 ± 0.7 2.9 ± 0.8 NS
Mean stent length per case, mm 31 ± 17 30 ± 17 NS
Contrast (mL) 160 ± 98 174 ± 83 NS
Glycoprotein IIb/IIIa inhibitors 22 (22%) 24 (24%) NS
Clinical state during angioplasty
SBP, mm Hg 135 ± 20 137 ± 17 NS
DBP, mm Hg 78 ± 12 77 ± 13 NS
HR, beats per minute 70 ± 14 71 ± 12 NS
Chest pain score > 1, n (%) 78 (78%) 54 (54%) 0.004
Complications, n (%)
Dissection 9 (9%) 8 (8%) NS
Jailed side branch (TIMI 0/1) 6 (6%) 7 (7%) NS
After stent implantation, n (%)
TIMI flow score 0–2 2 (2%) 2 (2%) NS
TIMI flow score 3 98 (98%) 98 (98%) NS
Data are presented as mean ± standard deviation, or number (%) of patients. CTO, chronic total occlusion; DBP,
diastolic blood pressure; DES, drug eluting stents; HR, heart rate; LAD, left anterior descending artery; LCx, left
circumflex artery; LM, left main artery; NS, not significant; PCI, percutaneous coronary intervention; RCA, right
coronary artery; PreC, remote ischemic preconditioning; SBP, systolic blood pressure; TIMI, thrombolysis in
myocardial infarction.
Table 3 Serum cardiac troponin I level at 24 hours and renal function at 72 hours after percutaneous coronary intervention.
Variable Control (N= 100) PreC (N= 100) P
cTnI, median (IQR) (ng/mL) 0.25 (0.03–0.91) 0.05 (0.02–0.63) 0.01
cTnI < 0.04 ng/mL, n (%) 25 (25%) 50 (50%) 0.005a
cTnI 0.04–0.12 ng/mL, n (%) 7 (7%) 6 (6%) 0.15a
cTnI 0.013–0.19 ng/mL, n (%) 4 (4%) 3 (3%) 0.15a
Incidence of MI 4a, (P0.20 ng/mL) 64 (64%) 41 (41%) 0.02a
Renal function
Peak eGFR (mL/min/1.73 m2) 73 (63–87) 64 (48–84) 0.001
D eGFR (mL/min/1.73 m2) 12% (0–18%) 7% (0–14%) 0.005
Peak SCr (mg/dl) 1.2 ± 0.38 1.0 ± 0.34 0.005
D SCr (mg/dl) 11% (0–19%) 6.5% (0–16%) 0.01
CIN, n (%) 11 (11%) 4 (4%) 0.05
Data are presented as median (interquartile range), number (%) of patients, or mean ± standard deviation. CIN, contrast induced
nephropathy; cTnI, cardiac troponin I; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MI, myocardial infarction; PreC,
remote ischemic preconditioning; SCr, serum creatinine. Delta (D), difference in mean between peak minus the baseline data.
a Wald test for logistic regression analysis using backward method.
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Figure 2 Study end points. Myocardial infarction, contrast
induced nephropathy incidence and parameter of renal dysfunc-
tion in patients receiving remote ischemic pre-conditioning and
control patients. MI4a = myocardial infarction type 4 a post-PCI,
CIN = contrast induced nephropathy, and eGFR = estimated
glomerular filtration rate.
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The target vessel characteristics and the final result of PCI
(predilation, postdilation, stent diameter, stent length and
number) were noted as described in detail previously.18,20
Angiographic lesion characteristics were classified according
to the modified AHA/American College of Cardiology classifi-
cation.25 Preprocedural and postprocedural assessments of
coronary blood flow (Thrombolysis In Myocardial Infarction
flow score) were performed.26 Other angiographic complica-
tions occurring during PCI (artery dissection, perforation, or
jailed side branch with compromised flow) and contrast dose
were noted. Two interventional cardiologists categorized each
case and were blinded to the participant’s details and the PCI
operators were blinded to the patient allocation group.
2.8. Outcome ascertainment
Patients recruitment started in September 2013 and ended in
May 2014. All patients were followed up for 3 months till
end of August 2014. Clinical outcome was evaluated through
the monitoring of MAE occurring at any time during the
follow-up as described in detail previously.18,20,27 Death was
defined as ‘‘all-cause” death at follow-up. Unstable angina/
acute coronary syndrome (ACS) was defined using standard
diagnostic criteria including cTnI release, ECG changes and
chest pain.15 A clinical diagnosis of heart failure (HF) during
follow-up was defined as either the presence of rales in more
than one-third of the lung fields that did not clear with cough-
ing or evidence of pulmonary edema on chest radiograph.
Hemodialysis as a complication of acute deterioration of renal
function post-PCI was also calculated. Only the most serious
event of MAE was used to calculate the cumulative
MAE per patient according to the following sequence:
Death > ACS >HF>Hemodialysis; this was described in
detail previously.27 MAE data were recorded by an indepen-
dent researcher without prior knowledge of the study alloca-
tion of the participants.
2.8.1. Outcome measures
The primary outcome measure of the study was to assess the
effect of PreC on the incidence of PCI-related MI 4a (using
cTnI level) at 24 h post-PCI. Secondary Outcome Measure
of the study was the incidence of CIN at 72 h after contrast
exposure. Other Pre-specified Outcomes include Chest pain
severity during PCI and MAE at 3 month follow-up.
2.9. Statistical methods and analysis
Statistical analysis was performed with SPSS version 16 soft-
ware (SPSS Inc). Although sample size was based on the
assumption of normality for the distribution of mean cTnI,
the extent of skewness in the distribution observed was such
that means could not be assumed to have a normal distribu-
tion. Therefore, analysis was based on nonparametric analysis
with the Mann–Whitney U-test. Clinical outcomes were pre-
sented as Kaplan–Meier survival estimates and were compared
using the log-rank test. Continuous variables were summarized
as mean ± standard deviation or as median (quartiles) and
compared by the Student’s t-test or a Wald test for logistic
regression analysis using backward method, as appropriate.Categorical data were expressed as numbers (percentages)
and compared by means of a Chi squared (v2) test and Fisher’s
exact test for dichotomous variables with fewer than 5 patients
in a category. A value of P< 0.05 was considered significant.
3. Results
3.1. Primary outcome measure
Both groups were comparable regarding baseline
demographic, clinical and angiographic data (Tables 1 and
2). Subjects were eligible for the study if the baseline cTnI
was below the lower limit of detection for the assay
(<0.04 ng/mL). After PCI, the median cTnI concentration at
Table 4 Clinical outcome and complications at 3 month
follow-up in the study groups.
Variable Control
(N= 100)
PreC
(N= 100)
P
Cumulative MAEb, n 14 6 0.04a
Death, n 0 0 –
ACS, n 12 6 0.059a
HF, n 1 0 0.9a
Hemodialysis, n 1 0 0.9a
Data are presented as number of patients.
a Compared using Chi-square or Fisher exact test.
b Only the most serious event was used per patient according to
the following sequence: death > ACS>HF>Hemodialysis.
MAE= major adverse events; ACS = acute coronary syndrome;
HF =Heart failure.
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mL (P= 0.01; Table 3). The incidence of MI 4a was lower in
the PreC group compared with the control group (41% vs
64%, P= 0.02; Table 3, Fig. 2).
3.2. Secondary outcome measure
Renal function assessment 3 days post-PCI showed a signifi-
cant trend toward lower incidence of CIN in the PreC group
compared to control group (Table 3, Fig. 2). Serum creatinine
increased by 11% (interquartile range: 0.0–19%) in the control
group versus 6.5% (interquartile range: 0.0–16%) in the PreC
group (P= 0.01, Fisher’s test). The eGFR decreased from a
median of 73 (interquartile range: 63–87) ml/min/1.73 m2 in
the control group to 64 (interquartile range: 48–84)
ml/min/1.73 m2 in the PreC group (p= 0.001). The decrease
in the eGFR was significantly more marked in control patients
compared with the PreC group (12% vs 7%, p= 0.005)
(Table 3, Fig. 2).Figure 3 Kaplan–Meier graph of the major adverse events.
Describes incidence of MAE over 6 months after PCI in the 194
patients with complete data (98 in the PreC group, 96 in the
control group). Cox regression analysis should a hazard ratio of
0.38 (95% CI, 0.14–0.98; P= 0.03).3.3. Pre-specified outcome measures
Subjects receiving PreC reported significantly less frequency of
chest pain during stent implantation (Table 2).
Of the 200 participants 6 were lost to follow-up at
3 months. Cumulative MAE occurred in 20 patients (10%);
the incidence of cumulative MAE was significantly lower in
the PreC group in comparison with the control group (6%
vs. 14%, p= 0.04) (Table 4). The Kaplan–Meier curves in
Fig. 3 illustrate a significant trend toward a higher MAE-free
survival at 3 months in the PreC group in comparison with
the control group (p= 0.03).
3.4. PCI-related complications
There were no major PCI-related complications in either group
(death or urgent revascularization within the first 24 h). Angio-
graphic and PCI-related parameters, clinical details during
procedure, and complication rates were similar in both groups
(Table 2).4. Discussion
The main findings in this study are as follows:
(A) PreC is easy, cheap and safe.
(B) The use of PreC < 2 h before PCI
1. reduces troponin release at 24 h post-PCI,
2. reduces type 4a MI in patients undergoing elective PCI,
3. reduces CIN at 72 h following contrast exposure, and
4. improves ischemic symptoms during PCI.
(C) PreC appears to confer a sustained benefit with reduced
MAE at 3 month follow-up beyond what is seen with
judicious pre- and post-hydration.
4.1. Reduction in troponin and type 4 MI
In our large prospective study, incidence of MI 4a was signif-
icantly reduced from 64% in the control group to 41% in the
PreC group; this means that 23 per 100 patients undergoing
elective PCI were saved from MI 4a in agreement with Luo
et al.28 where incidence of MI 4a was reduced from 54% to
39% in PreC group. Also Hoole et al.18 found that PreC
applied 1 h before PCI increased the number of patients
who had no detectable cTnI release at 24 h.
In contrast, Porto and colleagues29 observed that PreC
exacerbated cTnI release after PCI and enhanced the inflam-
matory response in the absence of statin therapy in low-risk
patients undergoing single-vessel elective PCI.
4.2. Reduction in contrast-induced necrosis
CIN after PCI is associated with a marked increase in morbid-
ity and mortality in short and long terms,30 with the principal
risk factor for its development being baseline renal impairment
or type of contrast used.19,24 In our study, there was a signifi-
cant trend of lower incidence of CIN in the PreC group com-
pared to control group (4 vs 11, p= 0.05). This concurs with
other prior work31 and one study20 that showed similar ampli-
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Wever et al’s.32 meta-analysis findings show that PreC effec-
tively reduces renal damage in animals, with higher efficacy
in the late window of protection. However the results of Hoole
et al.18 and Luo et al.28 failed to show any difference in the
incidence of CIN between the control and the PreC group.
The potential reasons for the difference from our findings
include the following: First, most of our participants had nor-
mal baseline renal function before PCI; Second, hydration for
high risk patients was given according to local protocols for
CIN prophylaxis; Third, more CIN occurred at 72 h than at
16 h after PCI as in Luo et al.28 or 24 h as in Hoole et al.18.
Yoon et al.33 recently concluded that the remote PreC might
require a considerable, rather than short, time window of
ischemia.
4.3. Improvement in symptoms during PCI
Intraprocedural chest discomfort during first coronary balloon
occlusion was significantly improved after PreC, in keeping
with acute cardioprotection during revascularization and other
studies.18 Creating preconditioning by blood pressure cuff to
cause transient ischemia of the upper limb was found to be well
tolerated and to have no adverse effects.
4.4. Long-term benefit
We continued clinical follow-up for 3 months to assess
whether there was a difference in hospitalization between those
patients who received PreC before PCI and the control sub-
jects. Patients who received PreC exhibited a lower MAE rate
(predominantly because of a reduction in acute coronary syn-
dromes), which comes in agreement with the data supporting
the better prognosis with the lower troponin release post-
PCI.12,13 Our results are in agreement with those of Hoole
et al.18 who also demonstrated a significant reduction in the
MAE rate including cardiac and cerebral events at 6 months
of follow-up. Also Deftereos et al.20 demonstrated that the
30-day rate of death or re-hospitalization for any cause was
significantly reduced from 22.3% in the control group to
12.4% in PreC patients (p= 0.05). Furthermore, Davies
et al.34 demonstrated a sustained long-term benefit of Pre-C
on clinical outcomes following PCI (around 6 years follow-
up). The mechanism for this effect is unknown. Precondition-
ing has a beneficial platelet inhibitory and antithrombotic
effect, which might stabilize vulnerable plaques, improve
endothelial function, and reduce inflammation.18 Further-
more, the effector signal-mediating myocardial protection
after limb ischemia through remote IPC is not defined and
appears to depend on both humoral and neuronal integrity.18
4.5. Prior studies
Transient limb ischemia prior to myocardial ischemia has been
shown to improve the extent of necrotic reperfusion injury and
endothelial function in animal models35 and significantly
reduces cardiac troponin and type 4a myocardial infarc-
tion18,34,36 and features of reperfusion injury on cardiac
MRI37 as markers of injury in humans following revasculariza-
tion for myocardial infarction. Our study results are consistent
with the above research and suggest that PreC is a safe andeffective strategy for providing cardioprotection when myocar-
dial necrosis is expected.
Conversely a study where PCI was carried out immediately
after preconditioning38 found no evidence of cardioprotection.
This study applied the preconditioning tourniquet ischemia for
shorter periods of three minutes, which may not have been suf-
ficient to evoke the protective signal. Also the preconditioning
stimulus was applied immediately before revascularization,
whereas we applied it <2 h before intervention. Our approach
allows a period for the first window of protection to be
triggered, which may have been missed in the other study.
4.6. Study limitations
Based on our study assignment method, patients were allo-
cated depending on the day they presented. This systematic
allocation process may lead to bias on the basis of foreknowl-
edge of treatment. Conversely angiographic data, laboratory
analysis and follow-up results were recorded by an indepen-
dent researcher without prior knowledge of the study alloca-
tion of the participants. This masking reduces the possibility
of bias for all the results except for the chest pain incidence
during PCI. The cTnI concentration was measured in a single
blood sample obtained 24 h after PCI rather than defining the
cTnI release profile every 4–6 h. The resultant value may not
be the maximum plasma concentration, although it is generally
accepted that the maximum concentration occurs between 12
and 24 h after myocyte necrosis. Finally the PreC was admin-
istered before <2 h before PCI, and the time from the first cuff
inflation to the first balloon dilation was not recorded in our
trial.5. Conclusion
The use of PreC < 2 h before PCI reduces the incidence of
PCI-related MI type 4a, decreases the incidence of CIN and
improves ischemic symptoms in patients undergoing elective
PCI. The observed cardio- and renoprotection appears to con-
fer sustained benefit on reduced MAE after PCI beyond what
is seen with judicious pre- and post-hydration.
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